MGMarina Grigolashvili

Marina Grigolashvili

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marina Grigolashvili has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comorbidity Burden and Early In‐Hospital Outcomes After Intravenous Thrombolysis for Acute Ischemic Stroke

    by Sharbanu Battakova, Marina Grigolashvili, Dmitry Kasatkin, Irina Kadyrova, Yelena Shayakhmetova, Mira Beisembayeva, Shynar Muratbekova, Ivan Turkevich, Alina Koshelyuk

    Background: The prognostic relevance of comorbidity burden in patients with acute ischemic stroke (AIS) treated with intravenous thrombolysis (IVT) remains uncertain. This study examined the association between four comorbidity indices and early in‐hospital outcomes. Methods: This single‐center retrospective study included 106 patients with AIS treated with IVT between January and December 2024. Comorbidity burden was assessed using the Charlson Comorbidity Index (CCI; 1987 and 2011 versions) and the Elixhauser Comorbidity Index (ECI; 2009 and 2017 versions). The primary outcome was unfavorable functional status at discharge, defined as a modified Rankin scale (mRS) score of 3–6. Multivariable logistic regression was used to identify factors associated with the primary outcome, and receiver operating characteristic (ROC) analyses assessed the discriminatory performance of the indices. Mortality comparisons were exploratory because only 10 in‐hospital deaths occurred. Results: The median age was 68 years, and 60 patients (56.6%) were men. Unfavorable functional outcome (mRS 3–6) occurred in 73 patients (68.9%). Higher admission National Institutes of Health Stroke Scale (NIHSS) scores and glucose levels were independently associated with unfavorable functional status at discharge, whereas none of the four comorbidity indices remained significant after multivariable adjustment. The comorbidity indices showed limited to modest discriminatory performance, with an AUC of 0.645 (95% CI 0.531–0.760) for CCI 1987. Hemorrhagic transformation (HT) occurred exclusively in patients with an unfavorable outcome and was more frequent among nonsurvivors. Exploratory comparisons also showed higher prestroke mRS, admission NIHSS, CCI 1987, and CCI 2011 scores among nonsurvivors; no multivariable mortality analysis was performed. Conclusions: None of the evaluated comorbidity indices was independently associated with functional status at hospital discharge. Their discriminatory performance was modest, whereas admission stroke severity and glucose level showed stronger associations with short‐term outcome. Given the retrospective single‐center design, modest sample size, and limited number of deaths, the findings should be considered exploratory and hypothesis‐generating and require confirmation in larger prospective studies.

  • Open Access

    Evaluation of Stroke Care Delivery: 12‐Month Experience of a Tertiary Stroke Center in Central Asia

    by Marina Grigolashvili, Dmitriy Klyuyev, Dmitry Kasatkin, Sharbanu Battakova, Yelena Shayakhmetova, Mira Beisembayeva, Shynar Muratbekova, Alina Koshelyuk, Yessenbay Baituyak, Ivan Turkevich, et al.

    The present study is a retrospective analysis of the activities of a tertiary stroke center (SC) operating on the basis of Akzhan Clinic in Karaganda Region during the year 2024. The primary objective of this study was to examine the epidemiological features, the structure of stroke morbidity, and the efficacy of thrombolytic therapy (TLT) in patients with ischemic stroke (IS). The study included data from a total of 585 patients, out of which 437 had been hospitalized with acute cerebrovascular disorders, and 104 of these patients had received TLT for IS. The analysis revealed a high level of utilization of TLT (23.8%), which was significantly higher than the average regional and national figures, owing to the efficient organization of prehospital and in‐hospital stages, availability of skilled personnel, and a state‐of‐the‐art technical infrastructure. Additionally, mechanical thrombectomy (MT) was performed in 100 instances, further confirming the high level of adoption of advanced treatment modalities. The proportion of hemorrhagic transformations (7.69%) and mortality (6.7%) was comparable to or lower than international benchmarks. The results demonstrate the high effectiveness of the performance of the SC “Akzhan” and the need for the further expansion of similar facilities in order to improve the accessibility and quality of stroke treatment in Kazakhstan.


  • Open Access

    A Comparative Analysis of the Gut Microbiota in Patients With Parkinson’s Disease Worldwide: A Systematic Review

    by Mira Beisembayeva, Yelena Shayakhmetova, Shynar Muratbekova, Irina Li, Eduard Yakupov, Rauan Kaiyrzhanov, Marina Grigolashvili

    Background: Parkinson’s disease (PD) is a neurodegenerative disease associated with the gut microbiome. Objective: Conducting a comparative analysis of the intestinal microbiome in PD patients from different geographical regions. Methods: Two researchers conducted a systematic literature review of the Web of Science, PubMed, and Scopus databases, using specific search terms and defined inclusion and exclusion criteria to select studies. This is the first systematic review that conducted an analysis of the gut microbiota of PD patients from all continents. Results: The α‐diversity of PD patients does not differ significantly from healthy individuals in Europe and America, in contrast to Asia and Australia. β‐Diversity varies among PD patients in different continents. In all regions, there has been an increase in Proteobacteria and Lactobacillaceae and a decrease in Lachnospiraceae and Roseburia . In Europe, Asia, and America, PD patients have shown an increase in Bifidobacteriaceae, Desulfovibrio , Verrucomicrobia, Bilophila , and Akkermansia and a decrease in Lachnospira . In Asia, America, and Australia, there has been a decrease in Fusicatenibacter and Lachnospiraceae ND3007 , while in Europe, America, and Australia, there has been a reduction in Butyricicoccus . Conclusions : There were no consistent patterns in the changes in α‐ and β‐diversities of the gut microbiota among PD worldwide. Across all continents, there was an increase in Proteobacteria and Lactobacillaceae and a decrease in Lachnospiraceae and Roseburia . Despite these similar trends, there were also differences that may be attributed to factors such as ethnic background, geography, and dietary habits. These differences suggest that individualized approaches to treatment may be necessary to effectively manage PD‐related gastrointestinal symptoms.